tradingkey.logo

Immix Biopharma Inc

IMMX
6.931USD
+0.191+2.83%
交易中 美东报价延迟15分钟
228.95M总市值
亏损市盈率 TTM

Immix Biopharma Inc

6.931
+0.191+2.83%

关于 Immix Biopharma Inc 公司

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.

Immix Biopharma Inc简介

公司代码IMMX
公司名称Immix Biopharma Inc
上市日期Dec 16, 2021
CEORachman (Ilya)
员工数量18
证券类型Ordinary Share
年结日Dec 16
公司地址11400 West Olympic Blvd.
城市LOS ANGELES
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编90064
电话18889581084
网址https://immixbio.com/
公司代码IMMX
上市日期Dec 16, 2021
CEORachman (Ilya)

Immix Biopharma Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Jason Hsu, Ph.D.
Mr. Jason Hsu, Ph.D.
Independent Director
Independent Director
4.86M
--
Dr. Nancy T. Chang, Ph.D.
Dr. Nancy T. Chang, Ph.D.
Director
Director
421.94K
+421940.00%
Ms. Helen C. Adams, CPA
Ms. Helen C. Adams, CPA
Lead Independent Director
Lead Independent Director
174.75K
-227.00%
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
173.19K
+107035.00%
Ms. Jane M. Buchan, Ph.D.
Ms. Jane M. Buchan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Carey Ng, Ph.D.
Mr. Carey Ng, Ph.D.
Independent Director
Independent Director
--
--
Mr. Gabriel Morris
Mr. Gabriel Morris
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Dr. Ilya Rachman, M.D., Ph.D.
Dr. Ilya Rachman, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Graham Ross
Dr. Graham Ross
Acting Chief Medical Officer, Head - Clinical Development
Acting Chief Medical Officer, Head - Clinical Development
--
--
Dr. Vladimir Torchilin, Ph.D.
Dr. Vladimir Torchilin, Ph.D.
Scientific Co-Founder
Scientific Co-Founder
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Jason Hsu, Ph.D.
Mr. Jason Hsu, Ph.D.
Independent Director
Independent Director
4.86M
--
Dr. Nancy T. Chang, Ph.D.
Dr. Nancy T. Chang, Ph.D.
Director
Director
421.94K
+421940.00%
Ms. Helen C. Adams, CPA
Ms. Helen C. Adams, CPA
Lead Independent Director
Lead Independent Director
174.75K
-227.00%
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
173.19K
+107035.00%
Ms. Jane M. Buchan, Ph.D.
Ms. Jane M. Buchan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Carey Ng, Ph.D.
Mr. Carey Ng, Ph.D.
Independent Director
Independent Director
--
--

收入明细

由于公司未披露,未能获取相关数据
由于公司未披露,未能获取相关数据
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 2月6日 周五
更新时间: 2月6日 周五
持股股东
股东类型
持股股东
持股股东
占比
Hsu (Jason)
9.32%
GKCC, LLC
6.21%
Rachman (Ilya M)
2.19%
The Vanguard Group, Inc.
2.10%
Ng (Carey)
2.00%
其他
78.17%
持股股东
持股股东
占比
Hsu (Jason)
9.32%
GKCC, LLC
6.21%
Rachman (Ilya M)
2.19%
The Vanguard Group, Inc.
2.10%
Ng (Carey)
2.00%
其他
78.17%
股东类型
持股股东
占比
Individual Investor
16.64%
Corporation
6.21%
Investment Advisor
5.13%
Investment Advisor/Hedge Fund
1.00%
Hedge Fund
0.21%
Venture Capital
0.07%
Research Firm
0.05%
其他
70.69%

机构持股

更新时间: 1月1日 周四
更新时间: 1月1日 周四
报告期
机构数
持股数
持股占比
持股变动
2025Q4
71
3.79M
7.26%
-825.10K
2025Q3
60
2.79M
8.55%
-1.92M
2025Q2
65
14.67M
52.67%
-1.12M
2025Q1
66
14.50M
53.34%
-1.02M
2024Q4
67
14.42M
52.43%
-1.29M
2024Q3
66
15.60M
56.77%
-243.92K
2024Q2
66
15.89M
59.32%
-308.72K
2024Q1
64
15.43M
77.52%
+5.90M
2023Q4
57
11.10M
62.12%
+3.00M
2023Q3
52
12.47M
73.23%
+2.63M
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
Hsu (Jason)
4.86M
9.32%
--
--
Apr 22, 2025
GKCC, LLC
3.24M
6.21%
--
--
Apr 22, 2025
Rachman (Ilya M)
1.14M
2.19%
+746.00
+0.07%
Dec 10, 2025
The Vanguard Group, Inc.
730.16K
1.4%
+31.63K
+4.53%
Sep 30, 2025
Ng (Carey)
1.05M
2%
--
--
Apr 22, 2025
Bleichroeder LP
850.00K
1.63%
--
--
Sep 30, 2025
Chang (Nancy T)
421.94K
1.29%
+421.94K
--
Sep 08, 2025
Morris (Gabriel S)
586.41K
1.12%
+770.00
+0.13%
Dec 10, 2025
Geode Capital Management, L.L.C.
187.48K
0.36%
+26.36K
+16.36%
Sep 30, 2025
Adams (Helen C)
174.75K
0.34%
-227.00
-0.13%
Apr 22, 2025
查看更多

持股ETF

更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
iShares Micro-Cap ETF
0.01%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
占比0.01%
Dimensional US Core Equity 1 ETF
占比0%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
除权除息日
类型
比率
暂无数据
公告日期
除权除息日
类型
比率
暂无数据
KeyAI